TISIDB

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
Domain	PF04130 Spc97 / Spc98 family
Function	Gamma-tubulin complex is necessary for microtubule nucleation at the centrosome.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0007020 microtubule nucleation GO:0007051 spindle organization GO:0007067 mitotic nuclear division GO:0007098 centrosome cycle GO:0007126 meiotic nuclear division GO:0031023 microtubule organizing center organization GO:0031109 microtubule polymerization or depolymerization GO:0031122 cytoplasmic microtubule organization GO:0046785 microtubule polymerization GO:0051225 spindle assembly GO:0051258 protein polymerization GO:0051297 centrosome organization GO:0051298 centrosome duplication GO:0051321 meiotic cell cycle GO:0051415 interphase microtubule nucleation by interphase microtubule organizing center GO:0051418 microtubule nucleation by microtubule organizing center GO:0090307 mitotic spindle assembly GO:1902850 microtubule cytoskeleton organization involved in mitosis GO:1903046 meiotic cell cycle process
Molecular Function	GO:0005200 structural constituent of cytoskeleton GO:0008017 microtubule binding GO:0015631 tubulin binding GO:0043015 gamma-tubulin binding GO:0051011 microtubule minus-end binding
Cellular Component	GO:0000923 equatorial microtubule organizing center GO:0000930 gamma-tubulin complex GO:0000931 gamma-tubulin large complex GO:0005813 centrosome GO:0005874 microtubule GO:0008274 gamma-tubulin ring complex GO:0032153 cell division site GO:0032155 cell division site part GO:0044450 microtubule organizing center part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-380287: Centrosome maturation R-HSA-69275: G2/M Transition R-HSA-453274: Mitotic G2-G2/M phases R-HSA-380320: Recruitment of NuMA to mitotic centrosomes R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TUBGCP6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TUBGCP6 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TUBGCP6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.065	0.78
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.19	0.893
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.019	0.987
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.212	0.533
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.23	0.935
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.191	0.958
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.154	0.656
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.408	0.786
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.092	0.955
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.062	0.964
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.968	0.582
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.16	0.0138

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TUBGCP6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	11.8	-7	0.577
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	33.3	0	33.3	0.0365
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TUBGCP6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TUBGCP6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TUBGCP6. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TUBGCP6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TUBGCP6 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TUBGCP6 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TUBGCP6
Name	tubulin, gamma complex associated protein 6
Aliases	GCP6; KIAA1669; DJ402G11.6; gamma-tubulin complex component 6; GCP-6; MCCRP; MCCRP1; MCPHCR
Chromosomal Location	22q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TUBGCP6 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TUBGCP6